Patent US4820805A successfully refreshed from Google Patents.
US4820805A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
Assignee: New York Blood Center
•
Filing: 1985-04-22
•
Granted: 1989-04-11
•
Expires: 2005-04-22
Abstract
Abstract A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
Inventors
- 👤 Alexander R. Neurath
- 👤 Bernard Horowitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 19:32
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2/16; A61L2/18; A61L2103/00; A61L2103/05; Y; Y10; Y10S; Y10S530/00; Y10S530/808; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
60 words
A process for obtaining a protein-containing composition which is substantially free of lipid-containing viruses without incurring substantial denaturation of any labile proteins contained therein, comprising contacting said protein-containing composition with an effective amount of di- or trialkylphosphate for a sufficient period of time, wherein said protein-containing composition is the product of a cancerous cell or the product of gene splicing.
Claim 2
Dependent Claim
60 words
A process for obtaining a protein-containing composition which is substantially free of lipid-containing viruses without incurring substantial denaturation of any labile proteins contained therein, comprising contacting said protein-containing composition with an effective amount of di- or trialkylphosphate for a sufficient period of time, wherein said protein-containing composition is the product of a cancerous cell or the product of gene splicing.
Claim 3
Dependent Claim
17 words
A process according to claim 1, wherein the protein-containing composition is a product of a cancerous cell.
Claim 4
Dependent Claim
16 words
A process according to claim 1, wherein the protein-containing composition is a product of gene splicing.
References Cited (Backward Citations)
US368250A
Cited
US3686395A
Cited
US3655871A
Cited
US3674864A
Cited
US4070454A
Cited
US3962421A
Cited
US4105650A
Cited
US4168300A
Cited
US4350707A
Cited
US4057628A
Cited
US4206014A
Cited
US4222934A
Cited
US4349539A
Cited
US4305871A
Cited
US4370264A
Cited
US4314997A
Cited
EP0050061A2
Cited
US4315919A
Cited
US4404187A
Cited
US4405603A
Cited
US4424206A
Cited
US4438098A
Cited
US4481189A
Cited
US4434093A
Cited
US4720385A
Cited
US4540573A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-10 | 1992-10-10 | 1993-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-10 | 1996-10-10 | 1997-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-10 | 2000-10-10 | 2001-04-11 | $7700.00 | Window Closed / Lapsed |